Literature DB >> 11777152

Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy.

R P Villareal1, P Kim, J J Ferguson, J M Wilson.   

Abstract

We reviewed recent clinical data on the management of unstable angina and non-ST segment elevation myocardial infarction. We concentrated on the use of new therapies, particularly in combination with both older agents and other new methods, in order to present health care providers with an overview of available treatment options. The clinical trials reviewed herein provide strong evidence and proof of principle that combination therapies targeting 1) platelet function (aspirin, thienopyridines, and GP IIb/IIIa antagonists), 2) the coagulation cascade (unfractionated heparin and low-molecular-weight heparin), and 3) the physical characteristics of the active lesion (percutaneous intervention) reduce the risk of death or ischemic complications after thrombotic progression of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11777152      PMCID: PMC101203     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  49 in total

1.  Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators.

Authors:  J J Young; D J Kereiakes; C L Grines
Journal:  J Invasive Cardiol       Date:  2000-12       Impact factor: 2.022

2.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).

Authors:  M E Bertrand; H J Rupprecht; P Urban; A H Gershlick
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

3.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  E Braunwald; E M Antman; J W Beasley; R M Califf; M D Cheitlin; J S Hochman; R H Jones; D Kereiakes; J Kupersmith; T N Levin; C J Pepine; J W Schaeffer; E E Smith; D E Steward; P Theroux; J S Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

4.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.

Authors:  J W Eikelboom; S S Anand; K Malmberg; J I Weitz; J S Ginsberg; S Yusuf
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

5.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.

Authors:  E Falk
Journal:  Circulation       Date:  1985-04       Impact factor: 29.690

6.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death.

Authors:  M J Davies; A Thomas
Journal:  N Engl J Med       Date:  1984-05-03       Impact factor: 91.245

7.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

8.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

Authors:  J A Cairns; M Gent; J Singer; K J Finnie; G M Froggatt; D A Holder; G Jablonsky; W J Kostuk; L J Melendez; M G Myers
Journal:  N Engl J Med       Date:  1985-11-28       Impact factor: 91.245

9.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

Authors: 
Journal:  Circulation       Date:  1998-06-23       Impact factor: 29.690

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.